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1. Introduction 
It is generally accepted that the outcome of oral malignant melanoma is worse than that of 
cutaneous and systemic head and neck melanoma. The five-year survival reported in the 
literature for oral melanomas varies from 0 - 20 % (Liversedge, 1975, Rapidis et al., 2003, 
Rapini et al., 1985), whereas the overall survival for head and neck melanomas ranges 
between 20 and 48 % (Guzzo et al., 1993, Patel et al., 2002, Stern and Guillamondegui, 1991, 
Temam et al., 2005), confirming anatomical site specific variation.  
Treatment modalities for primary oral melanoma include surgical resection with or without 
neck dissection. Adjunctive modalities such as immunotherapy, chemotherapy and 
radiation therapy may offer a supportive but as yet non curative role. The mainstay of 
curative treatment is surgery, mandating complete resection of the tumor with clear margins 
if possible (Rapini et al., 1985, Umeda and Shimada, 1994). Immunotherapy and 
chemotherapy are techniques which are  the subject of controlled trials or palliation 
(Mendenhall et al., 2005).  The rarity of oral malignant melanomas means that to date no 
randomized clinical trials have been conducted to establish an evidence base in the literature 
to provide comparisons of treatment modalities. The efficacy of surgery with planned 
supplementary radiotherapy remain unresolved and continue to generate controversy (Patel 
et al., 2002).  
Due the rarity of this disease, there is a lack of consistency in immunohistochemical 
confirmation of the diagnosis, staging strategies and treatment planning as diagnostic 
techniques and treatment have evolved over recent years in melanoma is other body sites 
and attempts have been made to translate these to the much rarer oral melanoma. This book 
section would like to aid the reader in understanding the current state of etiology, 
epidemiology, and treatment modalities of this very rare but aggressive tumor entity. 
2. Oral malignant melanoma 
The diagnosis of oral malignant melanoma often remains difficult. Differential diagnoses 
should include benign as well as malignant lesions and exogenous pigmentations can be 
often found (Figure 1). It also needs to be borne in mind that amelanotic malignant 
melanoma can affect the mouth, comprising one third of all oral malignant melanomas. 
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Fig. 1. Oral pigmentation due to inoculation of amalgam after dental treatment in the left 
buccal mucosa. 
The histological spectrum of benign pigmentations is wide: macular hyperpigmentation 
caused by junctional proliferation with or without cellular atypica, melanocytic naevi 
(Figure 2), such as junctional, compound, subepithelial, blue and combined naevi. Other 
causes of oral pigmentation include: race, Peutz-Jeghers syndrome (Daley and Armstrong, 
2007), Laugier-Hunziker syndrome (Mowad et al., 1997), Addison´s disease (Lamey et al., 
1985), patients with pulmonary diseases, especially in lung cancer (Merchant et al., 1976), 
and hemosiderosis. 
 
 
Fig. 2. Melanocytic naevi in the upper left vestibule. 
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Some authors describe a preexisting oral pigmentation for several month or years in one 
third of all patients with a primary oral malignant melanoma (Chaudhry et al., 1958, 
Liversedge, 1975, Rapini et al., 1985), although others found no correlation (Meleti et al., 
2007). The appearances of oral malignant melanomas vary and should always be considered 
in oral lesions without the tendency to heal (Figure 3). Remember that about 1/3 of all oral 
malignant melanomas are not pigmented (Anneroth et al., 1973, Chaudhry et al., 1958, 
Greene et al., 1953, Lengyel et al., 2003, Liversedge, 1975, Rapidis et al., 2003). 
 
 
Fig. 3. Intraoral view of a malignant melanoma arising from the palate. 
2.1 Etiology 
Melanomas are categorized into four different types according to anatomic region and 
pathological factors: 1. melanomas arising from skin without chronic sun damage, 2. 
melanomas on skin with chronic sun damage, 3. acral melanomas, and 4. mucosal 
melanomas (Curtin et al., 2006). The etiology of primary oral malignant melanoma is still 
unknown. Cigarette smoking, denture irritation and alcohol have been mentioned as 
possible risk factors, but evidence remains obscure. Intraoral malignant melanomas arise 
from melanocytic cells of the oral cavity, which represent a minority of all cells of the 
mucosal membrane. Although just a few melanocytes are present in the oral mucosa the 
potential to develop malignant melanomas clearly exist. Indeed it is recognized that 
malignant melanoma can very rarely develop in almost any organ suggesting that 
circulating melanocytes may be responsible. About 5-30 % of primary malignant melanomas 
are preceded by oral pigmentations for months or even years. It has been suggested that 
melanosis represents the initial phase characterized as the radial phase of growth and 
precedes the invasion of underlying tissues (vertical growth) by years, however the 
histological spectrum of benign pigmented lesions is wide and a pre-existing pigmented 
lesion is not usually associated with mucosal melanomas. Most arise as new lesions, from 
apparently healthy mucosa.  
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Malignant melanomas develop from melanocytes derived from the neural crest. The most 
frequently primary sites in the oral cavity are the palate and maxillary gingiva (Barker et al., 
1997, Hicks and Flaitz, 2000, Lee et al., 1994). Mucosal melanomas are considered to be more 
aggressive tumors compared with cutaneous melanomas and they are more inclined to 
metastasize into regional and distant sites, recur locally or regionally resulting in a high rate 
of disease specific-death. 
2.2 Epidemiology 
Malignant melanoma in the head and neck area is rare. Oral cavity primary malignant 
melanoma comprises 6.3 % of all melanomas in the head and neck area and only about 0.7 – 
1.6 % of all melanomas arise in the oral mucosa (Chang et al., 1998, Moore and Martin, 
1955). The incidence of primary mucosal melanomas of the head and neck is approximately 
four per 10 million population per year (Hicks and Flaitz, 2000). The most frequently 
affected  oral sites are the palate and maxillary gingiva (Barker et al., 1997, Hicks and Flaitz, 
2000, Lee et al., 1994). The incidence  in Japan  is much higher than in western countries, in 
which it occurs with less than 1%  (Batsakis, 1982, Brandwein et al., 1997, Umeda and 
Shimada, 1994). The age of the patients varies between 20 and 80 years, the mean age 
reported in the literature ranges from 56 to 66.5 years (Gorsky and Epstein, 1998, Hicks and 
Flaitz, 2000, Patel et al., 2002, Rapidis et al., 2003, Rapini et al., 1985) and a modest  male 
preponderance has been described (Rapini et al., 1985). 
2.3 Prognosis 
The prognosis is adverse. Due to delayed diagnosis early  invasion of surrounding tissue, 
local lymph node involvement and distant metastasis, the prognosis of oral mucosal 
melanomas is very poor. The reported 5-year survival rates vary in the literature between 6 
and 18 % but also between 45 and 48 % (Enroth CM, 1975, Lee et al., 1994, Lund, 1993, Ravid 
and Esteves, 1960, Stern and Guillamondegui, 1991). Gingival melanoma has a slightly 
better 5-year survival rate (18%) than that of palatal melanoma (11%), with a longer median 
survival period (46 months vs. 22 months). These wide variations are probably due to the 
fact that comparable classifications are still not agreed internationally. The routine use of 
tumor thicknessof mucosal melanomas, as described by the Breslow or the Clark levels are 
not widely performed as a routine method in everyday experience (Prasad et al., 2003, 
Prasad et al., 2002, Thompson et al., 2003). Therefore an evidence base derived 
fromhistopathological assessment and subsequent prognosis for malignant mucosal 
melanomas is lacking.Despite this many reports  show a correlation between tumor 
thickness and prognosis (Mücke et al., 2009, Prasad et al., 2004). Many authors agreed that 
the survival rate was not only closely related to the stage of the tumor, but the treatment 
that patients received (Mücke et al., 2009, Prasad et al., 2003, Prasad et al., 2004, Rapidis et 
al., 2003, Rapini et al., 1985, Tanaka et al., 2004, Temam et al., 2005). 
The vast majority of the head and neck mucosal melanomas are Stage 1 at the time of 
presentation , Prasad et al defined a 3-level-microstaging system, which represents different 
microanatomical compartments separated by tissue barriers. They found out that this 
microstaging system is prognostically significant and an independent predictor concerning 
the 5-year survival rate and the recurrence-free survival (Mücke et al., 2009, Prasad et al., 
2004). In 2009, the American Joint Committee on Cancer (AJCC) Melanoma Staging 
Committee used previously published guidelines and determined criteria which were used 
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in the TNM classification and the stage groupings (Balch et al., 2009). These criteria are 
established for all kinds of melanomas and are proposed as follows:  
1. In patients with localized melanoma, tumor thickness, mitotic rate, tumor burden, and 
ulceration were the most important prognostic factors.  
2. The mitotic rate indicates the level of invasion as a primary criterion for defining T1b 
melanomas.  
3. Components that defined the N category were the presence and number of metastatic 
nodes of the primary melanoma.  
4. All patients with microscopic nodal metastases, regardless of extent of tumor burden, 
are classified as stage III.  
5. On the basis of a multivariate analysis of patients with distant metastases, the two 
dominant components in defining the M category continue to be the site of distant 
metastases and an elevated serum lactate dehydrogenase level. 
Factors that have been associated with worse disease-specific survival include clinical stage 
at presentation, thickness of the tumor, tumor burden at the time of staging (microscopic vs. 
macroscopic), presence or absence of primary tumor ulceration, presence of vascular 
invasion, melanosis, and development of nodal and distant metastasis (p < 0.001) (Balch et 
al., 2009). Multiple local recurrences are the most common cause of treatment failure and 
may occur 10-15 years after primary treatment. The most common sites of distant metastases 
include the lungs, brain, liver and bones.  
2.4 Staging 
The criteria to verify the presence of a primary intraoral melanoma are: 
1. demonstration of clinical and microscopic tumor in the oral mucosa 
2. presence of junctional activity in the lesion 
3. inability to show any other primary site. 
All patients have to fulfill all these criteria to verify the diagnosis of primary oral malignant 
melanoma (Greene et al., 1953). In addition to the standard staging procedure, patients 
should be observed by means of: sonography, gastroscopy and bronchoscopy in order to 
exclude other potential primary sites and confirm by exclusion the diagnosis of primary oral 
mucosal malignant melanoma (Mücke et al., 2009). It is important to confirm the 
comparatively rare finding of primary oral mucosal malignant melanoma is supported by 
exclusion of other potential mucosal sites for example the respiratory and the 
gastrointestinal tract, which are more frequently found than oral melanomas (Lee et al., 
1994, Mendenhall et al., 2005, Prasad et al., 2003).  
Patients should be staged according the TNM Melanoma Staging System of the American 
Joint Committee on Cancer which includes in the staging the extent of the tumor status as 
well as the extent of the nodal status, but does not provide a specific guideline for oral 
mucosal melanomas. Therefore a simplified staging system has been established, which 
classifies tumors in 3 stages: Stage I to localized disease, confined to the primary site, stage II 
the primary lesion with cervical lymph node metastasis and stage III for distant metastasis.  
As previously described there is a 3-level-microstaging system which relates to the prognostic 
outcome. In this system each level represents a microanatomical compartment, which is 
defined through tissue barriers.Breach of each barrier correlates with a progressively worse 
survival rate. Level I is defined as an in situ mucosal melanoma or microinvasion, Level II as 
an invasion limited to lamina propria  and Level III is defined as melanoma with a deep 
invasion into surrounding tissue such as bone cartilage or skeletal muscles.  
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2.5 Histopathology 
The surface architecture from oral melanomas ranges from macular to ulcerated and 
nodular. As recommended at the WESTOP (Western Society of Teachers of Oral Pathology) 
Banff  Workshop, oral malignant melanomas should be separately considered from the 
cutaneous forms and proposed to subclassify them according to the histological pattern into: 
in situ melanoma, invasive, combined (invasive melanoma with in situ components) and 
atypical melanocytic proliferation (in case where diagnosis is equivocal) (Barker et al., 1997). 
In situ melanomas are limited to the epithelium and the epithelial-connective tissue 
interface, and represent 15% of the oral melanomas. They show a proliferation of atypical 
melanocytes characterized through hyperchromatic and angular nuclei with infrequent 
mitotic activity. The melanocytes may be arranged irregularly at the epithel connective 
tissue-interface or may be distributed in aggregates.  
Invasive pattern in which the melanoma extend into the connective tissue is represented in 
30% of oral melanoma, showing a wide range of cell types including spindle, plasmocytoid, 
clear cells and epithelioid, arranged into sheets or organoid/alveolar formation. The large 
and vesicular nuclei appear frequently with prominent nucleoli and rare mitosis. 55% of oral 
melanomas having combined pattern, which is typical for advanced lesions (Barker et al. 
1997, Femiano et al. 2008). 
In most instances melanomas contain melanin pigmented tumor cells but amelanotic 
melanoma show a lack of melanin production, which exacerbates the correct diagnosis, 
because amelanotic melanoma can mimic a variety of poorly differentiated carcinoma or cell 
lymphoma. For distinguishing these melanomas from other tumors immunohistochemical 
stains have been proven to be helpful. For differential diagnosis, it should be claimed that 
immunhistochemical staining of the following markers is mandatory and the basis of the 
diagnosis of an oral malignant melanoma.  
Immunohistochemical markers include S-100  protein, gp100 (HMB-45) and Mart-1 (Melan- 
A) (Messina et al., 1999). These markers are also used for the identification of 
micrometastases in lymph nodes (Messina et al., 1999). 
The Antibody HMB-45 reacts with the melanosomal glycoprotein gp100, showing a positive 
staining in active early melanosome formation and showing epithelioid lesions intensily 
immunoreactive for HMB-45. It is considered as more specific but less sensitive than the S-
100 protein, an acidic calcium binding protein, which is a very sensitive marker for nevus 
and melanoma cells, and even spindled lesions appear intensely immunoreactive for S-100 
protein (Blessing et al., 1998, Gazit and Daniels, 1994). Melan-A is considered to be specific 
for melanoma cell lines, as a product of the MART-1 gene it is a melanocytic differentiation 
marker which is recognized on melanomas as an antigenic target of T lymphocytes 
(Kawakami et al., 1994). 
In recent years some molecular markers, like the Ki67 antigen emerged as potentially 
prognostical indicators, however the role of potential therapeutic relevance of KIT inhibitors 
in mucosal melanoma further needs to be investigated. 
2.6 Therapy 
Regarding the treatment of the four types of melanomas, melanomas arising from skin 
without chronic sun damage, melanomas on skin with chronic sun damage, acral 
melanomas and mucosal melanomas, most authors agree that radical ablative surgery with 
wide local excision of the primary lesion and dissection of metastatic lymph nodes are the 
basis of every curative therapy (Curtin et al., 2006). Controversial points are the margin of 
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the excision, the optimal time to dissect the local lymph nodes, and the uncertainty of the 
extent of lymph nodes dissection. Surgery is the mainstay of treatment but can only be 
accomplished if vital parts of the body are not affected and therefore anatomical limitations 
often make a radical excision impossible. 
The following protocol refers to the extent of margins: 
1. Excision of the primary lesion including at least 1 – 2 cm of healthy tissue based on the 
primary tumor extent and thickness 
2. Lymph node dissection and removal of lymph node metastases 
3. Consideration of radiochemotherapy (limited evidence as to the benefit of 
postoperative radiotherapy exists for other anatomical sites). 
2.6.1 Surgery 
Principles defined by the first tumor resection in 1857 remain viable today in that the 
treatment of all melanomas should be performed by wide resection. Cutaneous melanomas 
are still treated by that principle to avoid local recurrence (Essner, 2003, Hauschild et al., 
2003, Veronesi and Cascinelli, 1979). Limited excision of the primary lesion as well as 
excisional and incisional biopsies are associated with an increased risk of causing accidental 
dissemination of malignant cells within the adjacent tissues or even into the blood or 
lymphatic stream with probable devastating consequences (Harter et al., 1992, Kusukawa et 
al., 2000).  
The surgical margin also depends on the thickness of the tumor. In patients with tumors less 
than 1 mm thickness, a surgical margin of 1 cm has been shown to be adequate, compared 
with wide tumor margin resections of 3 cm (Veronesi et al., 1988). None of these patients 
developed local recurrence in the follow-up period revealing an adequate resection extent. 
In patients with tumor thickness of 1 to 2mm local recurrences were found in both study 
groups of patients receiving resection margins of 1 cm or 3 cm without significant 
differences, although more recurrences were found in the 1 cm group (Veronesi et al., 1988). 
The evidence, that  resections of 1 to 2 cm around the tumor are sufficient and show similar 
results in local control and overall survival, have been also found by other studies 
comparing the long term results of different resection protocols in varying tumor extent and 
thicknesses (Balch et al., 1993, Heaton et al., 1998). The local recurrence rate in these studies 
is  1.7% with 2 cm surgical margin compared with 0.8% with 4 cm after six years without 
statistically significant differences (Balch et al., 1993, Heaton et al., 1998). The surgical 
therapy within the oral cavity remains problematic because wide resection margins require 
also reconstruction techniques after tumor ablation to avoid mutilation, functional 
impairment and a poor quality of life (Mücke et al., 2009, Mücke et al., 2011, Mücke et al., 
2010). In some instances the suggested resection margins would compromise vital structures 
which mean a compromise between theoretically ideal margins and postoperative function 
and quality of life must be made.  
Regional lymph nodes are the most common sites of metastases for all melanomas. Palpable 
lymph nodes in the neck or fixed to the adjacent tissues should be suspicious for metastases. 
Radiologically, lymph nodes larger than 1 cm must also be considered to be involved by 
metastases. There exists a correlation between the tumor thickness and the occurrence of 
regional lymph node metastases.  Primary lesions less than 1 mm thickness are considered 
to yield a rate of < 10% lymph node metastases, 1.01 to 2.00 mm are accounting for about 
20%, 2.01 to 4.00 mm are accounting for 33%, and >4.00 mm are associated with a risk of 
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lymph node involvement of more than 40%  at the time of staging (Morton et al., 2005, 
Morton et al., 2003, Morton et al., 1993). Another study evaluated an exponential increasing 
of lymph node metastases if the tumor becomes thicker. A thickness of 0.76 to 1.50 mm was 
associated with regional lymph node metastases in 2 to 25% of cases. In tumors with a 
thickness between 1.51 to 4.00 mm the rate of regional lymph node metastases developed to 
57%. A tumor thickness larger than 4 mm was associated with microscopic presence of 
metastases within the lymph nodes (Balch, 1999, Balch et al., 2000, Balch et al., 1996). There 
has been evidence that lymph node dissection resulted in an increase of overall survival 
compared to patients receiving palliative treatment to the neck only (Balch, 1999, Balch et 
al., 2000, Balch et al., 1996, Balch et al., 1993, Cascinelli et al., 1998). Negative lymph nodes 
are a strong prognostic factor for survival, whereas lymph node metastases yield a 6 times 
higher relative risk for death (Balch et al., 2009, Gershenwald et al., 1999). 
Patients who suffered from oral mucosal malignant melanomas are often diagnosed at an 
advanced stage followed by ulceration, microsatellites or regional nodal  metastases 
(Chaudhry et al., 1958, Morton et al., 1993, Mücke et al., 2009, Patel et al., 2002, Prasad et al., 
2004, Rapidis et al., 2003, Temam et al., 2005). This high rate of regional lymph node 
metastases means that patients at risk should be considered for therapeutic elective neck 
dissection with a low threshold for surgery. Although no randomized trials on the treatment 
of the regional lymph nodes for oral mucosal malignant melanoma exist due to the rarity of 
this tumor, there is little doubt about this treatment approach. (Balch et al., 2009, Balch et al., 
1996, Cascinelli et al., 1998, Chaudhry et al., 1958, Essner, 2003, Hauschild et al., 2003, 
Medina et al., 2003, Morton et al., 2003, Morton et al., 1993, Mücke et al., 2009, Patel et al., 
2002, Tanaka et al., 2004, Temam et al., 2005). As the oral melanoma is very aggressive and 
the texture of the mucosa is different from the cutis with an earlier occurrence of lymph 
node metastases, there is actually no role for the sentinel lymph node technique, as the risk 
of micrometastases has to be excluded by standard therapeutic neck dissection (Prasad et al., 
2004, Snow and van der Waal, 1986, Umeda and Shimada, 1994). 
2.6.2 Radiotherapy 
Radiotherapy has been used to control local recurrence (Balch et al., 1993, Harwood, 1983, 
Schmidt-Ullrich and Johnson, 1996, Storper et al., 1993). Postoperative, adjuvant radiation 
therapy results in a lower local recurrence rate in comparison to patients without 
radiotherapy treated by wide surgical resection only (Harwood, 1983). Hyperfractionated 
accelerated radiotherapies have appeared most useful (Harwood, 1983, Schmidt-Ullrich and 
Johnson, 1996, Storper et al., 1993), although the differences were not found to be 
statistically significant. The adjuvant performance of radiotherapy should be considered in 
advanced stage malignant melanomas of the oral cavity.  There are still no data available 
from randomized trials regarding the efficacy of adjuvant radiotherapy. 
2.7 Adjuvant therapy 
Adjuvant therapy modalities vary and include the application of non-specific 
immunostimulants (Grooms et al., 1977, Morton et al., 1970, Morton et al., 1974, Sondak and 
Wolfe, 1997), specific immunstimulants (Interferons), vaccination therapy, cytotoxic 
chemotherapy, and target-therapy.  
Non-specific immunstimulants like Bacille Calmette-Guérin (BCG), Cryptosporidium 
parvum, Levanisole, thymosin, isoprinosine, transfer factor and retinoids, and interleukin 
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had been applied by local injection into the tumor (Grooms et al., 1977, Morton et al., 1970, 
Morton et al., 1974, Sondak and Wolfe, 1997). Although some authors reported limited 
evidence that survival was increased by this therapy this adjuvant therapy failed to prove 
an advantage in comparison with control treatment of any kind. Most studies performed 
were retrospective studies (Grooms et al., 1977, Morton et al., 1970, Morton et al., 1974, 
Sondak and Wolfe, 1997). 
After non-specific immunostimulants have failed to establish an effect on overall survival or 
an improvement of symptoms, attention was paid to more specific immunostimulants such 
as Interferons. These glycoproteins showed a immunmodulatory and anti-tumoral effect, 
which was thought to be beneficial in melanoma patients. Expression of major 
histocompatibility complex molecules, enhancing of antigen presentation by dendritic cells, 
inhibition of angiogenesis, and a directly antiproliferative effect combined with the 
expression of melanoma-specific antigen and the stimulation of natural killer cells directly 
affecting the tumor was a promising treatment modality (Ascierto and Kirkwood, 2008, 
Janku and Kurzrock, 2010, Jonasch and Haluska, 2001, Jonasch et al., 2000, Kalani et al., 
2008, Pfeffer et al., 1998). Unfortunaetly early enthusiasm has waned and this strategy is 
more and more critically debated  (Janku and Kurzrock, 2010). The effect of interferon-α 
(IFN-α) has been well evaluated in different clinical trials in melanoma patients and a dose-
dependent and duration-dependent effect has been found, especially in high-risk patients 
with the presence of lymph node metastases or thick melanoma patients (Kirkwood et al., 
2001, Kirkwood et al., 1996, Punt and Eggermont, 2001). In contrast, high-dose IFN-α is often 
associated with severe toxicity (Eggermont, 2002, Eggermont and Gore, 2002), and the 
outcome reported by the Southwest Oncology Group revealed no clinical benefit for patients 
who received adjuvant therapy. Indeed they  may have done worse when compared to the 
patients who received no adjuvant therapy (Barth and Morton, 1995, Taylor et al., 1992).  
Another adjuvant method for the therapy of melanoma patients are vaccination therapies. 
Based on the evidence that the immune system plays a natural role in melanoma 
progression in the same way that the previous treatment modalities tried to act at the same 
mechanism, vaccination therapy is designed to activate the host immune response to tumor 
- associated antigens. In the lack of information about specific tumor antigens, the tumor cell 
was the best source of antigens for activating the immune system (Hersey et al., 2002, 
Hersey et al., 1987, Sun et al., 1999). Previous methods of producing vaccines are always 
based on tumor cell preparations, but there is still no role for vaccination therapies in oral 
malignant melanomas. 
The most established therapy beside surgery combined with radiotherapy remains cytotoxic 
chemotherapy. Multiple trials about a variety of cytotoxic drugs in adjuvant treatment have 
been performed but no study demonstrated benefits of adjuvant chemotherapy in 
melanoma patients at high risk for relapse or affecting overall survival significantly in 
controlled randomized trials. The mainstay of chemotherapy remains the palliative 
situation. The mainstays of cytotoxic chemotherapy include; dacarbazine, the nitrosoureas, 
the vinca alkaloids, cisplatin, paclitaxel, and bleomycin. The use of additional 
chemotherapeutic agents is still evolving. Single-drug therapy with dacarbazine reported an 
objective response in 18-22% of patients with measurable metastatic disease (Hill et al., 1979, 
Hill et al., 1981, Houghton et al., 2006, Houghton et al., 1996, Lee et al., 1995). Some trials 
describe  efficacy of dacarbazine as a postsurgical adjuvant, but suggested no significant 
clinical benefit in the treatment of patients with high risk melanoma (Hill et al., 1979, Hill et 
al., 1981, Veronesi et al., 1982). Multiagent cytotoxic therapy is similarly unhelpful in the 
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adjuvant setting. Other trials of multiagent chemotherapy using nitrosoureas, dactinomycin 
and vincristine present contrary results (1983, Castel et al., 1991, McClay et al., 2000, Pawlik 
and Sondak, 2003, Wood et al., 1978).  
3. Conclusion 
The incidence of oral melanoma is very low and results of the treatment are still poor partly 
due to the advanced stage of tumor at presentation. No single management strategy or 
guideline can be considered the standard of care on the basis of current data. Within the 
head and neck the extent of the tumor, spread to the regional lymph nodes, systemic disease 
and histopathological variables have to be integrated into the disease staging and related to 
the patients’ co-morbidities and personal aims. Radicality of resection has to be balanced 
against the feasibility of reconstruction of the resected area obtaining form and function as 
well as the quality of life the patient requires. Treatment of oral mucosal malignant 
melanoma may not be entirely consistent with the treatment of cutaneous malignant 
melanoma. The thickness of the primary lesion, stage of regional lymph nodes, sex, age, the 
reaction of the lesion to treatment are important factors influencing prognosis and treatment 
choices of the disease. To date, due to the rarity of this tumor entity, no randomized trials 
exist demonstrating any optimal treatment algorithm.  
Multicenter studies collecting data about the treatment strategies and outcomes of patients 
suffering from oral malignant melanomas are necessary to identify the best treatment 
algorithm based on patient related clinical work. Oral melanomas are different from 
cutaneous melanomas and such studies would provide us a far better insight into their 
behaviour. The tumor thickness is a variable that most accurately determines therapy and 
prognoses, therefore, the extent of surgery margins should be decided based on the invasive 
depth of the primary lesion, the neck addressed on the basis of imaging staging but with a 
low threshold for intervention. Reconstruction follows conventional approaches but 
adjuvant therapy is currently disappointing.   
An increasing understanding of tumour immunology and biology has led to innovative 
therapies which are necessary if an effective treatment for oral malignant melanomas is to be 
developed in the future. The application of new or established technologies in experimental 
tumor models is necessary to increase the potential for such treatments (e.g. proteomics, 
targeted therapy, vaccination therapy), but is currently still an area of experimentation and 
hope rather than pragmatic clinical practice.  
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